Novel CDK4/6 Inhibitor

53.8% ORR with Fulvestrant

A selective CDK4/6 inhibitor that shows promising antitumor activity and good tolerability when combined with fulvestrant in HR+/HER2− advanced breast cancer.

Zhang, Jian · Liu, R. · Gao, S. P. · Wang, Y. · Chen, M. J. · Hu, Xichun

ESMO Open 2025

Specifications

确认的客观缓解率

{'zh': '53.8', 'en': ''} %

疾病控制率

{'zh': '87.2', 'en': ''} %

Half-life of approximately

{'zh': '', 'en': '51.1'} hours

联合氟维司群

{'zh': '500', 'en': ''} mg